Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL

Raj Chovatiya; Matthew Zirwas; Melinda J Gooderham; Christine Bangert; Rodney Sinclair; Marjolein de Bruin-Weller; Stephan Weidinger; Carmen Tsang; Caitriona McCarthy; Andrew Selfridge; Pinaki Biswas; Herwig Koppensteiner; Claire Feeney; Sara Ramaker; Gary Chan

doi:10.1080/09546634.2026.2712186

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL

Raj Chovatiya^*
, Matthew Zirwas
, Melinda J Gooderham
, Christine Bangert
, Rodney Sinclair
, Marjolein de Bruin-Weller
, Stephan Weidinger
, Carmen Tsang
, Caitriona McCarthy
, Andrew Selfridge
, Pinaki Biswas
, Herwig Koppensteiner
, Claire Feeney
, Sara Ramaker
, Gary Chan

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: JADE REAL was a global, prospective, multicenter, open-label expanded access protocol study that integrated the rigorous follow-up, safety, and efficacy assessments of a clinical trial with dosing flexibility and ability to use concomitant topical therapies to simulate real-world management of atopic dermatitis (AD).

OBJECTIVE: The study aimed to provide access to abrocitinib for patients with moderate-to-severe AD without adequate treatments available.

METHODS: Eligible patients received abrocitinib 100 mg or 200 mg once daily per investigator's discretion. Dose could be adjusted during treatment. Safety and exploratory efficacy endpoints were assessed.

RESULTS: Of 312 patients, 120 (38.5%) and 192 (61.5%) received an initial dose of abrocitinib 100 mg and 200 mg, respectively. TEAEs were reported in 78.2% of patients. TEAEs led to dose change in 39 patients (12.5%); 12 (3.8%) had a dose escalation and 27 (8.7%) had a dose reduction. Rapid improvements in AD severity progressed up to 72 weeks among observed patients.

CONCLUSION: Most patients continued their initial dose of abrocitinib. TEAEs accounted for a minority of documented dose reductions; instead, investigators may have determined that the patients' disease could be maintained at a lower dose. These findings support clinical decision-making around dose selection and modification.

TRIAL REGISTRATION: NCT04564755.

Original language	English
Article number	2712186
Number of pages	10
Journal	The journal of dermatological treatment
Volume	37
Issue number	1
Early online date	7 Aug 2026
DOIs	https://doi.org/10.1080/09546634.2026.2712186
Publication status	E-pub ahead of print - 7 Aug 2026

Keywords

Humans
Dermatitis, Atopic/drug therapy
Female
Male
Prospective Studies
Severity of Illness Index
Pyrimidines/administration & dosage
Treatment Outcome
Adult
Adolescent
Dermatologic Agents/administration & dosage
Dose-Response Relationship, Drug
Young Adult
Child
Middle Aged
Sulfonamides

Access to Document

10.1080/09546634.2026.2712186Licence: CC BY-NC

Simulating real-world abrocitinib use in atopic dermatitis results from JADE REALFinal published version, 2.56 MBLicence: CC BY-NC

Cite this

Chovatiya, R., Zirwas, M., Gooderham, M. J., Bangert, C., Sinclair, R., de Bruin-Weller, M., Weidinger, S., Tsang, C., McCarthy, C., Selfridge, A., Biswas, P., Koppensteiner, H., Feeney, C., Ramaker, S., & Chan, G. (2026). Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL. The journal of dermatological treatment, 37(1), Article 2712186. Advance online publication. https://doi.org/10.1080/09546634.2026.2712186

@article{bf307d16017740a19a166fe65837eb71,

title = "Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL",

abstract = "BACKGROUND: JADE REAL was a global, prospective, multicenter, open-label expanded access protocol study that integrated the rigorous follow-up, safety, and efficacy assessments of a clinical trial with dosing flexibility and ability to use concomitant topical therapies to simulate real-world management of atopic dermatitis (AD).OBJECTIVE: The study aimed to provide access to abrocitinib for patients with moderate-to-severe AD without adequate treatments available.METHODS: Eligible patients received abrocitinib 100 mg or 200 mg once daily per investigator's discretion. Dose could be adjusted during treatment. Safety and exploratory efficacy endpoints were assessed.RESULTS: Of 312 patients, 120 (38.5\%) and 192 (61.5\%) received an initial dose of abrocitinib 100 mg and 200 mg, respectively. TEAEs were reported in 78.2\% of patients. TEAEs led to dose change in 39 patients (12.5\%); 12 (3.8\%) had a dose escalation and 27 (8.7\%) had a dose reduction. Rapid improvements in AD severity progressed up to 72 weeks among observed patients.CONCLUSION: Most patients continued their initial dose of abrocitinib. TEAEs accounted for a minority of documented dose reductions; instead, investigators may have determined that the patients' disease could be maintained at a lower dose. These findings support clinical decision-making around dose selection and modification.TRIAL REGISTRATION: NCT04564755.",

keywords = "Humans, Dermatitis, Atopic/drug therapy, Female, Male, Prospective Studies, Severity of Illness Index, Pyrimidines/administration \& dosage, Treatment Outcome, Adult, Adolescent, Dermatologic Agents/administration \& dosage, Dose-Response Relationship, Drug, Young Adult, Child, Middle Aged, Sulfonamides",

author = "Raj Chovatiya and Matthew Zirwas and Gooderham, \{Melinda J\} and Christine Bangert and Rodney Sinclair and \{de Bruin-Weller\}, Marjolein and Stephan Weidinger and Carmen Tsang and Caitriona McCarthy and Andrew Selfridge and Pinaki Biswas and Herwig Koppensteiner and Claire Feeney and Sara Ramaker and Gary Chan",

year = "2026",

month = aug,

day = "7",

doi = "10.1080/09546634.2026.2712186",

language = "English",

volume = "37",

journal = "The journal of dermatological treatment",

issn = "0954-6634",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

Chovatiya, R, Zirwas, M, Gooderham, MJ, Bangert, C, Sinclair, R, de Bruin-Weller, M, Weidinger, S, Tsang, C, McCarthy, C, Selfridge, A, Biswas, P, Koppensteiner, H, Feeney, C, Ramaker, S & Chan, G 2026, 'Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL', The journal of dermatological treatment, vol. 37, no. 1, 2712186. https://doi.org/10.1080/09546634.2026.2712186

TY - JOUR

T1 - Simulating real-world abrocitinib use in atopic dermatitis

T2 - results from JADE REAL

AU - Chovatiya, Raj

AU - Zirwas, Matthew

AU - Gooderham, Melinda J

AU - Bangert, Christine

AU - Sinclair, Rodney

AU - de Bruin-Weller, Marjolein

AU - Weidinger, Stephan

AU - Tsang, Carmen

AU - McCarthy, Caitriona

AU - Selfridge, Andrew

AU - Biswas, Pinaki

AU - Koppensteiner, Herwig

AU - Feeney, Claire

AU - Ramaker, Sara

AU - Chan, Gary

PY - 2026/8/7

Y1 - 2026/8/7

N2 - BACKGROUND: JADE REAL was a global, prospective, multicenter, open-label expanded access protocol study that integrated the rigorous follow-up, safety, and efficacy assessments of a clinical trial with dosing flexibility and ability to use concomitant topical therapies to simulate real-world management of atopic dermatitis (AD).OBJECTIVE: The study aimed to provide access to abrocitinib for patients with moderate-to-severe AD without adequate treatments available.METHODS: Eligible patients received abrocitinib 100 mg or 200 mg once daily per investigator's discretion. Dose could be adjusted during treatment. Safety and exploratory efficacy endpoints were assessed.RESULTS: Of 312 patients, 120 (38.5%) and 192 (61.5%) received an initial dose of abrocitinib 100 mg and 200 mg, respectively. TEAEs were reported in 78.2% of patients. TEAEs led to dose change in 39 patients (12.5%); 12 (3.8%) had a dose escalation and 27 (8.7%) had a dose reduction. Rapid improvements in AD severity progressed up to 72 weeks among observed patients.CONCLUSION: Most patients continued their initial dose of abrocitinib. TEAEs accounted for a minority of documented dose reductions; instead, investigators may have determined that the patients' disease could be maintained at a lower dose. These findings support clinical decision-making around dose selection and modification.TRIAL REGISTRATION: NCT04564755.

AB - BACKGROUND: JADE REAL was a global, prospective, multicenter, open-label expanded access protocol study that integrated the rigorous follow-up, safety, and efficacy assessments of a clinical trial with dosing flexibility and ability to use concomitant topical therapies to simulate real-world management of atopic dermatitis (AD).OBJECTIVE: The study aimed to provide access to abrocitinib for patients with moderate-to-severe AD without adequate treatments available.METHODS: Eligible patients received abrocitinib 100 mg or 200 mg once daily per investigator's discretion. Dose could be adjusted during treatment. Safety and exploratory efficacy endpoints were assessed.RESULTS: Of 312 patients, 120 (38.5%) and 192 (61.5%) received an initial dose of abrocitinib 100 mg and 200 mg, respectively. TEAEs were reported in 78.2% of patients. TEAEs led to dose change in 39 patients (12.5%); 12 (3.8%) had a dose escalation and 27 (8.7%) had a dose reduction. Rapid improvements in AD severity progressed up to 72 weeks among observed patients.CONCLUSION: Most patients continued their initial dose of abrocitinib. TEAEs accounted for a minority of documented dose reductions; instead, investigators may have determined that the patients' disease could be maintained at a lower dose. These findings support clinical decision-making around dose selection and modification.TRIAL REGISTRATION: NCT04564755.

KW - Humans

KW - Dermatitis, Atopic/drug therapy

KW - Female

KW - Male

KW - Prospective Studies

KW - Severity of Illness Index

KW - Pyrimidines/administration & dosage

KW - Treatment Outcome

KW - Adult

KW - Adolescent

KW - Dermatologic Agents/administration & dosage

KW - Dose-Response Relationship, Drug

KW - Young Adult

KW - Child

KW - Middle Aged

KW - Sulfonamides

U2 - 10.1080/09546634.2026.2712186

DO - 10.1080/09546634.2026.2712186

M3 - Article

C2 - 42565345

SN - 0954-6634

VL - 37

JO - The journal of dermatological treatment

JF - The journal of dermatological treatment

IS - 1

M1 - 2712186

ER -

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL

Abstract

Keywords

Access to Document

Fingerprint

Cite this